Trials / Completed
CompletedNCT00394082
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Celgene · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-007 | 125 mg/m\^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle. |
| DRUG | Bevacizumab | Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1. |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2009-09-01
- Completion
- 2011-02-01
- First posted
- 2006-10-31
- Last updated
- 2019-11-25
- Results posted
- 2013-05-22
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00394082. Inclusion in this directory is not an endorsement.